Indolent lymphoma · 13 regimens
Cost vs Efficacy · 6 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Bendamustine and Ofatumumab Variant #01 | — | R 1 183 782 | 28d | — | — | — | — | — |
Fludarabine and Rituximab (FR) Variant #06 | — | R 117 749 | 28d | — | — | — | — | — |
Lenalidomide and Rituximab (R2) Variant #10 | — | R 86 746 | 35d | ~39.4 mo | — | ~35 | ~R 3 036 103 PFS proxy · indirect | 1 |
Bortezomib and Rituximab (VR) Variant #06 | — | R 64 235 | 35d | ~12.8 mo | — | ~12 | ~R 770 814 PFS proxy · indirect | 1 |
R-CHOP Variant #23 | — | R 59 865 | 21d | 44.4 mo | — | 65 | R 3 891 219 PFS proxy | 1 |
Bendamustine and Rituximab (BR) Variant #12 | — | R 40 807 | 28d | 69.5 mo | — | 76 | R 3 101 329 PFS proxy | 2 |
R-CMD Variant #01 | — | R 31 214 | 21d | — | — | — | — | — |
VR-CHOP Variant #01 | — | R 14 802 | 21d | — | — | — | — | — |
R-CVP Variant #01 | — | R 12 182 | 21d | — | — | — | — | 1 |
Chlorambucil monotherapy Variant #12 | — | R 2 523 | 14d | ~12.6 mo | ~69.7 mo | ~28 | ~R 70 639 PFS proxy · indirect | 6 |
PCR N/A - secondary systemic drug Partial | — | R 172 | 28d | — | — | — | — | — |
Rituximab monotherapy N/A - secondary systemic drug | — | R 52 | 180d | ~17.7 mo | — | ~3 | ~R 156 PFS proxy · indirect | 4 |
Watchful waiting Partial | — | — | — | ~12.9 mo | — | — | — | — |
13 of 13 regimens shown